Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist
申请人:Nycomed GmbH
公开号:EP1849468A2
公开(公告)日:2007-10-31
The invention relates to the combined administration of PDE4 or PDE3/4 inhibitors and histamine receptor antagonists for the treatment of respiratory diseases.
本发明涉及联合使用 PDE4 或 PDE3/4 抑制剂和组胺受体拮抗剂治疗呼吸系统疾病。
SUCCINIMIDE AND MALEIMIDE CYTOKINE INHIBITORS
申请人:CELGENE CORPORATION
公开号:EP0862552A1
公开(公告)日:1998-09-09
US5658940A
申请人:——
公开号:US5658940A
公开(公告)日:1997-08-19
[EN] SUCCINIMIDE AND MALEIMIDE CYTOKINE INHIBITORS<br/>[FR] SUCCINIMIDES ET MALEIMIDES INHIBITEURS DE LA CYTOKINE
申请人:CELGENE CORPORATION
公开号:WO1997012859A1
公开(公告)日:1997-04-10
(EN) Novel succinimides and maleimides are inhibitors of tumor necrosis factor $g(a) and phosphodiesterase and can be used to combat cachexia, endotoxic shock, retrovirus replication, asthma, and inflammatory conditions. A typical embodiment is methyl 3-(3',4',5',6'-tetrahydrophthalimido)-3-(3',4'-dimethoxyphenyl)propionate.(FR) L'invention concerne de nouveaux succinimides et maléimides inhibiteurs du facteur de nécrose tumorale $g(a) et de la phosphodiestérase, que l'on peut utiliser pour traiter la cachexie, le choc endotoxique, la réplication de rétrovirus, l'asthme et les maladies inflammatoires. Dans une variante classique, il se présente sous la forme méthyle 3-(3',4',5',6'-tétrahydrophtalimido)-3-(4',4'-diméthoxyphényl)propionate.
[EN] NEW COMBINATION<br/>[FR] NOUVELLE COMBINAISON
申请人:ALTANA PHARMA AG
公开号:WO2003024488A2
公开(公告)日:2003-03-27
The invention relates to the combined administration of PDE4 or PDE3/4 inhibitors and leukotriene receptor antagonists for the treatment of respiratory tract disorders.